



February 14, 2024

Company name: PeptiDream Inc.  
Representative: Patrick C. Reid, President and CEO  
(Securities code: 4587; TSE Prime Market)  
Inquiries: Yuko Okimoto, Head of Investor Relations  
(Tel: +81-44-223-6612)

## Notice Regarding PeptiDream's Participation in Tender Offer

PeptiDream Inc. (President and CEO: Patrick C. Reid, Headquarters: Kawasaki City, Kanagawa Prefecture, hereinafter "Company") announced today that the Board of Directors has resolved to subscribe to the tender offer (the "Tender Offer") conducted by Bristol Myers Squibb Company for all of the 1,163,579 shares of common stock of RayzeBio, Inc ("RayzeBio") held by the Company.

### 1. Reasons for participating in the Tender Offer

The Company decided to participate in the Tender Offer because 1. The Board of Directors of RayzeBio unanimously approved the Tender Offer and 2. the conditions of the Tender Offer, including the purchase price, were reasonable.

### 2. The number of shares to participate in the Tender Offer

The number of shares the Company holds: 1,163,579

The number of shares to participate in the offer: 1,163,579

The number of shares after participation to the offer: 0

### 3. The outline of the Tender Offer

Offer Price: 62.50 USD per share

Tender Offer Period: January 25, 2024 to February 22, 2024

If the Tender Offer is successful, the Company expects to receive approximately 10.5 billion JPY as consideration for the sale of its RayzeBio shares in the first quarter of the fiscal year ending December 2024. As a result, we expect to record an approximately 9.3 billion JPY gain on the sale of the RayzeBio shares as extraordinary income in our non-consolidated income statement (*Japanese GAAP*) for the fiscal year ending December 2024. In our consolidated accounting (*International Financial Reporting Standards*), the increase in market value of the Company's stake in

RayzeBio has already been reflected as other comprehensive income in the consolidated statement of income for the fiscal year ending December 2023, therefore the impact to consolidated results for the fiscal year ending December 2024 is expected to be minor.

*Note 1: Based on the assumption that this tender offer is successful. If any matters arise in regards to this transaction, they will be promptly announced.*

*Note 2: 1 USD = 147 JPY*